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1. Introduction 
The present report describes my on-the-job training experience as a Medical Science Liaison at 
AstraZeneca and is submitted in partial fulfillment of the requirements for the Master’s degree in 
Pharmaceutical Medicine. The internship was nine months long and started on 8th April, 2014. 
Regarding structure and contents, the report is organized in six chapters: 
 The first chapter includes, apart from training objectives, a portrayal of AstraZeneca’s 
structure, with a special focus on the Medical & Regulatory Affairs department. 
Chapter two presents a brief description of new paradigms of organizational models in 
pharmaceutical industry, highlighting the most important changes occurred in the last few years 
and the impact of those across the most prominent world’s markets. 
Chapter three entails a description of Medical Affairs’ activities in modern pharmaceutical                                                                                                                                                                                                 
companies and its approach on interfacing responsibilities and medical education.  
Chapter four introduces the new emerging role of Medical Science Liaison, where its core 
responsibilities in science, communication, Key Opinion Leaders (KOLs) management, insights-
driver and, more extensively, in medical education, underlining practice trends across 
pharmaceutical industry are presented.  
The last chapters are reserved to detail the on-the-job training as Medical Science Liaison 
where, independently of other core activities related to the function, my role in managing of 
medical education projects are emphasized.  
Additionally, in these final chapters, simultaneously as critical appraisal and conclusion, my 
expectations, achievements, major challenges and contributions during this experience as a 
trainee are also described.  
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2. New paradigms of pharmaceutical industry 
There are different nature forces changing the way pharmaceutical industry will operate in the 
near future: pressure for lower cost medications, payer’s mergers, healthcare reforms, 
uncertainty around delivering the promise of pipelines, extremely high costs associated to 
research and development, and regulatory demands are reshaping pharmaceutical industry’s 
business model. In the United States of America and, similarly, in Europe, the increasing 
healthcare costs, the structural healthcare system reforms as well as heavier fiscal burdens are 
implying a thorough cost control by governmental authorities.1  
These challenges have reinforced the need to demonstrate and communicate value beyond 
what was initially standard, based on the “orthodox” clinical development program and taking the 
classical “physicians stakeholders” into consideration only. Today, increasingly relevant players 
(e.g. payers, pharmacy & therapeutics (P&T) committee members) have an important decision 
role, and pharmaceutical companies have to be ready to communicate effectively with these 
stakeholders, using different and more sophisticated and complex evidence. 1 Also, as science 
evolves towards more specialized treatment options and personalized health care, new scientific 
concepts and technologies are at stake, and companies need to secure the right certified people 
and capabilities so that they can communicate product’s value proposition. These changing forces 
have made clear to innovation-driven pharmaceutical companies the increasing relevance of the 
Medical Affairs teams and their evolving role. 
Finally, as a result of regulatory demands for more transparency and higher public exposition 
of pharmaceutical industry, the way companies are engaging with Health Care Professionals 
(HCPs) and Public officials is being increasingly scrutinized, with physicians tending to refrain from 
being paid for participation as industry’s speakers in sponsored events, fearing that it may affect 
their credibility and integrity, which underpins conflicts of interest matters and the need to 
properly address this as part of the daily business. 1 These regulatory pressures that ask for more 
transparency regarding access to patient data, and ethical interactions with HCPs and third 
parties, have also led pharmaceutical industry to create stricter compliance procedures, with a 
particular focus on Medical Affairs, due to its critical role in dissemination of data and external 
interfacing. 1 
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3. Medical Affairs in modern pharmaceutical companies 
In the recent past, the majority of strategic responsibilities resided on the commercial and 
marketing teams.2 Over the last years, as a reaction to more restrictive regulatory demands and 
commitment to greater transparency, Medical Affairs emerged with a fully separated role from 
commercial departments, shifting their focus away from marketing support to KOLs interfacing 
and medical communication activities. Although marketing support traditionally represents a 
Medical Affair activity it is no longer considered its main focus, and much of the work is now 
included under KOL management, compliance activities and medical education. Progressively, 
Medical Affairs have taken a more strategic role within pharmaceutical companies, intervening 
not only in post-approval period, but in all drug lifecycle, including prelaunch phase, guarantying a 
stable and reliable foundation to its products commercialization. 3 
Currently, Medical Affairs include several medical activities, such as medical field teams (which 
include Medical Science Liaisons, who drive scientific exchange and deliver product information to 
medical community), post-launch clinical trials (including the planning and execution of phase 
IIIb/IV sponsored interventional and observational studies, investigator-initiated studies and 
pharmacoeconomic studies), medical information services, medical communications (including 
the support for peer-reviewed publications), medical education (including the identification of 
educational gaps about a disease, product or treatment, and implementation of external medical 
education programs according with the assessed needs, and the training of internal teams), 
medical strategic activities (including development of the medical plan for each product, 
collaborating cross-functionally with other departments to create a product life-cycle strategy). 1 
Examples of other Medical Affairs functions in a modern pharmaceutical company include: 3, 4 
 Ensure adherence to ethical standards, legal requirements and guidelines; 
 Provide a medical perspective to product development; 
 Provide medical insights to support marketed products commercial strategy throughout 
their life cycle; 
 Management of KOLs and OPs; 
 Response to HCPs medical queries regarding product safety or efficacy that is not 
addressed in a product’s label; 
 Support research initiatives outside labeled indications for marketed products; 
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 Work collaboratively and compliantly with different company departments (marketing, 
market access, regulatory affairs, training, legal) to ensure full medical support; 
 Collect and report adverse events, and support to other pharmacovigilance activities; 
 Promotional materials review and approval. 
Medical Affairs may organize and structure themselves in different footprints.  Many 
pharmaceutical companies choose to implement a centralized organization in which global teams 
implement and execute the strategies within global medical plans with a direct local market roll-
out.  In turn, other companies work with fully decentralized functions in which each country 
implement their own medical plans adapted to local market needs and characteristics.  It is also 
possible to implement a hybrid structure and organization, with both centralized and 
decentralized characteristics, extracting each one’s benefits. 5  
3.1. Industry and medical education 
In post World War II period, in the 1950s and 1960s, there was an escalation of medical 
innovation and subsequent drug promotion on behalf of pharmaceutical industry. During these 
years, pharmaceutical companies developed broad intellectual and financial relationships with 
physicians, academic researchers and their institutions, relying on them to develop and maintain 
innovative research projects. In this partnership with physicians and academic researchers, 
pharmaceutical companies earned access to the forefront work being developed in the medical 
and biomedical research fields. Reciprocally, physicians and academic researchers gained access 
to fundamental research funds and sponsored medical education. The interactions between 
pharmaceutical companies, physicians, academic researchers, and their institutions developed 
mutual interests and shared needs. 6, 7 
Simultaneously, pharmaceutical industry realized the existence of a commercial opportunity in 
marketing its products to physicians. Companies felt that it was in their best interest to contribute 
to the spreading of new medical knowledge, while guaranteeing their visibility amongst HCPs.  A 
partnership between medical community and pharmaceutical industry at physicians’ medical 
education level emerged as a natural consequence of this interaction. Nevertheless, as industry 
sponsor for medical education grew, so did concerns about its commercial influence. Potentially 
seen as «incentives», these brought clear conflicts of interests. So, to protect patient’s interests 
and to minimize pharmaceutical’s commercial bias among medical community, strict regulatory 
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standards were progressively developed. Nowadays, sponsored medical education is highly 
regulated and follows high ethical standards to guaranty transparency and full separation 
between promotional and non-promotional contents. 6, 8 
Medical education can be defined as an activity « (...) designed for, or performed by a physician 
for the purpose of acquiring, maintaining, or upgrading knowledge, skills, or attitudes to improve 
the quality of the healthcare that the physician dispenses to patients. (...) may be an individual or 
group action, based on a need or an interest, being a part of the learning process». 9 
Medical education activities may take the form of a live presentation, internet-based 
presentation, videotape, teleconference, print medium, publications, Continuous Medical 
Education as scientific meetings (symposium, scientific updates, advisory boards, expert meetings, 
investigator meetings) or others, and may be certified by an accredited provider (academia, 
professional associations, medical education agencies).  
These activities are strategically planned to support product and therapeutic area knowledge, 
and therefore establish the scientific basis for product differentiation. They also allow 
pharmaceutical companies: 
 to build KOLs infrastructure (global, national, regional and local) through consulting, 
training and education;  
 to publish and communicate key data and information;  
 to present scientific and clinical information to target audience encouraging the 
improvement of patient outcomes; 
 to use data, theory and experience to broaden the message and strengthen the 
product image. 
Although Continuous Medical Education is crucial to enable healthcare providers to acquire 
new medical knowledge and skills after the completion of the academic training, in Portugal it has 
a voluntary character, unlike other European countries like France, Italy, and Germany where it is 
formally compulsory. 10, 11 
Despite the differences between Continuous Medical Education systems of European 
countries, healthcare authorities and medical associations are considered the main Continuous 
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Medical Education providers, leaving pharmaceutical industry sponsorships accounts for more 
than 50% of the programs.11 In Portugal, Continuous Medical Education is largely driven by 
pharmaceutical industry. 12 
3.2. Ethics, compliance and regulatory standards 
In the last years, incidents involving pharmaceutical industry and medical community 
highlighted the fragility of the prevailing regulatory framework, revealing obvious conflicts of 
interest in this interaction. These discussions brought to light public distrust regarding 
pharmaceutical industry and particularly its potential influence amongst physicians. 
Ever since, pharmaceutical industry and governments made significant efforts to ensure 
compliant, ethical communication and transparent interactions with medical community.13 
Concerning Medical Education, in Portugal, articles 150, 160 and 161 from Decree-Law nr. 
176/2006 – Estatuto do Medicamento 14, article 19 from Decree-law nr. 330/90 – Código da 
Publicidade 15 and Deliberation nr. 044/CD/2208 16,, establish the legal frame of the sponsorship of 
scientific and educational programs involving HCPs, having INFARMED as the regulatory authority. 
The deontological code from the local Pharmaceutical Association, APIFARMA - Código 
Deontológico para as Práticas Promocionais da Indústria Farmacêutica e para as Interacções com 
os Profissionais de Saúde in its articles 16 to 22 - supports in a more practical way the legal 
designations.17 
Furthermore, each company has its own strict compliance guidelines, usually designated as 
conduct code, supported by different policies, guidance and standards, which are aligned with 
referent regulatory and legal requirements, ethical standards and company’s values.  
These documents have emerged to help industry to establish appropriate interaction with 
HCPs, and share a common perspective to protecting people’s welfare and needs above 
commercial interests. 
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4. The role of Medical Science Liaison (MSL) 
Most of major pharmaceutical companies have implemented field-based, customer facing 
medical support, composed by specialists with advanced training and degrees in life sciences that 
deliver a broad range of services to Opinion Leaders (OPs) and  KOLs), clinical investigators and 
decision makers in healthcare institutions. As a consequence of their advanced academic training, 
and clinical and/or scientific background, field-based medical professionals are considered as 
more knowledgeable and verisimilar than sales representatives especially in what regards the 
exchange of scientific information. The role of field-based medical professionals has evolved over 
the years with the introduction of new and more complex products, and the increased 
sophistication of physicians’ information requirements and education needs.18 
These field-based specialists are commonly designed as Medical Science Liaisons. However 
each company structures the MSL role differently so there are several designations used for these 
positions: regional medical liaison, clinical advisor, scientific affairs liaison, scientific affairs 
manager, and regional medical associate, among others. 19, 20 
Regardless the designations of the MSL may be slightly different, the role definition shares 
common aspects: 
The Medical Science Liaisons are «specialists with advanced training and degrees in life 
sciences that are traditionally employed to educate healthcare professionals on a company’s 
therapeutic capability in a given stage of a product’s lifecycle».21 
«Medical liaisons develop and enhance relationships with key opinion leaders within the health 
care community to contribute to improve outcomes for patients. Activities of medical liaisons 
include dissemination of medical information upon request, exploration of mutual clinical and 
scientific interests with health care providers, facilitation of professional education, and 
understanding the dynamics and unmet needs within therapeutic areas».22 
«(…) field-based position whose main mission is to foster collaborative relationships with key 
opinion leaders (KOLs) and to facilitate the exchange of unbiased scientific information between 
the medical community and the company. (…) the major objective is to develop the professional 
relationships with the healthcare community, particularly KOLs, through peer to peer contact. (…) 
facilitate investigator‑initiated clinical research proposals from approval until completion, 
presentation, and publication. (…) assist in the development, review, and follow-up of the clinical 
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studies initiated within the relevant therapeutic area at the regional/local level. (…) lead 
regional/local clinical projects to ensure that all clinical trials are conducted in compliance with the 
International Conference of Harmonization Good Clinical Practice (ICH GCP) guidelines». 20 
While the common driver of the definition of MSL is KOLs management and scientific 
exchange, their scope of activities are varied, evolving and highly dependent on each company’s 
perspective and strategy.21 
4.1. Historical facts 
Although considered as a new trend, first Medical Science Liaisons team was originally created 
in 1967 by Upjohn Company. It started with a small group of sales representatives with increased 
scientific background, and whose main objective was enhancing the company’s image amongst 
researchers and KOLs, engaging them in peer-to-peer interactions, collecting insights on their 
needs and leveraging Upjohn products into research activities.18 
Ever since, Medical Science Liaison role has been evolving in a way that current Medical 
Science Liaisons activities are impacting outcomes for patients in a widely scale. This is 
accomplished by dissemination of medical information, by searching mutual clinical and scientific 
interests with physicians, by encouraging medical education, and by apprehending the dynamics 
and unmet needs within therapeutic areas.18, 23 
4.2. MSL function overview 
Today, the MSL role comprises a wider scope of internal and external activities with different 
stakeholders. These activities are tailored according to companies’ core business, pipeline, drug 
lifecycle phase, structure, organization, strategies and available resources.  
Another relevant aspect of MSL role is related to geographical allocation of the teams, which 
may vary from small to large range geographies. The impact of large coverage territories implies 
high costs and time consuming travels. On the other hand, small regions coverage allows 
companies to optimize the MSL activities, both internally and externally.24 Each company 
establishes its own criteria based on country specificities and KOLs’ panel dimension. 
The success of the MSL role depends upon its ability to accomplish the strategic objectives 
assigned on the medical plan while strictly adhering to all relevant compliance guidelines. As more 
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complex and demanding activities emerged, so did the necessity of an accurate MSL performance 
measurement able to evaluate competitive intelligence, insights and capable of demonstrating 
the real contributions of MSLs for company’s internal value. 25 
Medical education, exploration of post-approval studies opportunities, KOL management and 
insight support to medical strategy, compose some of the different roles in which a MSL may be 
enrolled, and are described below.  
4.2.1. Role in Medical Education 
Medical education is considered a key activity of the MSL.19 As they develop and enhance 
relationships with KOLs and other HCPs within medical community, MSLs promote scientific 
exchange, in-depth and cutting-edge information about products, presenting data in an objective, 
scientifically balanced, accurate and substantiated manner, ethical, truthful and free of 
promotional contents. Acting as KOLs’ scientific partners, MSLs explore mutual clinical and 
scientific interests, identifying medical educational gaps and unmet needs, collecting these 
insights to build relevant and appropriate continuous medical education programs.26 This 
interaction with HCPs promote advance in disease mechanisms and processes understanding and 
lastly, enhance patient access to optimal medical treatment and best use of it. 
Interacting with the medical community in the context of medical education implies the 
following activities: 
 Provide on-label information and deliver access to ongoing clinical trial information;27 
 Respond to unsolicited requests for information about unapproved products or 
unapproved uses of approved products, which requires full transparency on the 
treatment’s entire profile and a clear presentation of all risks and benefits, based on 
the latest status of medical and scientific research; 18 
 Implement appropriate continuous medical education activities by: targeting 
educational voids, identifying and engaging speakers, reviewing scientific data to 
prepare them; support several medical projects such as clinical trials, investigator-
sponsored studies, non-interventional studies and scientific exchange meetings; 
provide recommendations for advisory board participants and present data. 21 
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As result of their specialized role, KOLs state that MSLs are a very important resource for their 
practice, being able to discuss conceptually about overall disease state, efficacy issues and up to 
date research and science trends (Figure 1 – Importance of MSL Abilities and Attributes from 
KOLs’ perspective). The results from a survey conducted to describe the MSL importance from a 
KOLs’ perspective, show that the most valuable attributes of the MSL rely on their ability to act in 
an ethical manner, their awareness of specific therapeutic emergent products, their 
comprehensive knowledge about the disease state, their ability to address efficacy questions and 
to being up to date on current research trends. 21 
Figure 1 – Importance of MSL Abilities and Attributes from KOLs’ perspective (adapted from Moss & Black, 2013) 
The MSLs need to have a deep understanding of the KOLs circumstances, their challenges, 
needs and concerns. And it is based on this understanding that they can create value to KOLs 
practice, patients and institutions, being recognized as scientific drivers of valuable information 
that have significant impact on clinical practice and in patients lives. 21 
From companies’ perspective, the interaction between MSLs, KOLs and other HCPs, in the 
context of medical education, brings important insights about medical community unmet needs 
and competitive intelligence that turns to be useful to better shape medical and brand plans, 
when integrated via Brand Teams or other cross-functional structure. 
«Currently, due to very restrictive policies governing the relationship between pharmaceutical 
industry and medical community, became mandatory the growth of medical affairs towards 
scientific excellence communication, guarantying high ethical standards between the parties. 
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Among the many scientific tools that Medical Affairs make use of to sustain a highly ethical 
relationship with medical community, medical education projects are the "gold standard". Here 
the value of the MSL is unquestionable, being involved since early planning: giving very 
constructive scientific inputs - resulting from their expertise; streamlining with insights collected 
from KOLs tailoring the operationalization of projects, with respective  micro-management of 
KOLs, as well as communicating scientific evidence contents  back to physicians. We are living 
challenging times. And only companies with a well sustained Medical Affairs structure will survive 
to the scientific demands of medical community. Here, the MSL is certainly one of the values to 
success». Dr Rafael Fernandes, CV& Metabolic Medical Affairs Manager AstraZeneca 
Bridging the gap of physicians’ educational needs, the MSL reinforces the scientific bond 
between company and medical community and the shared purpose, which is putting patients on 
the center of everything they do. 
4.2.2. Role in research 
A potential expanding area for MSLs is clinical trials or research-related activities, which have 
been emerging as a focus for the future. These activities are intertwined with responsibilities in 
the support of investigator-initiated studies and company-sponsored trial. Furthermore, there are 
other types of studies supported by MSLs, which include health outcomes-related studies, health 
policy studies, and post-marketing studies. The role of MSLs within these activities goes from 
direct site management of studies supporting the start-up phases as well as recruitment, to 
problem-solving with clinical research organization (CRO), and also investigator meeting support 
(round table facilitation, data training presentations). 23 
Besides the support activities, the MSLs have also the responsibility of exploring new research 
needs for marketed products (phases IIIB and IV studies), which can include, in addition, the 
identification of potential investigators. In this context, MSLs assume the role of clinical 
catalysts.25, 28 
Currently, the majority of MSLs are involved in clinical trials activities but only a small part of 
their daily work is related to these activities. This emergent involvement tends to grow as Medical 
Science Liaison support throughout all drug lifecycle continues to increase. 23 
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4.2.3. Role in KOL management 
The development and communication of breakthrough science and innovative compounds are 
core to the success of a innovation-driven company. To boost and optimize the strategic planning 
it is essential to build KOL and thought leader relationships. 
KOLs and thought leaders are individuals who are considered references in research and in 
academic world, and are often seen as trendsetters and guides to their therapeutic areas by their 
peers.19 
 The engagement of these professionals starts, inevitably, with medical education. By 
delivering cutting-edge and valuable information, education and training, pharmaceutical 
companies grow as KOL’s scientific partners. In turn, KOLs contribute with their insights to ensure 
that brand strategy maximizes the medical benefits for patients and physicians.  
Moreover, engaging KOLs as speakers on behalf of the companies in medical education events 
has advantages not only to the companies in the dissemination of their information, but also to 
medical community, who gain access to unbiased, reliable, updated clinical and medical evidence. 
The MSL embodies the formal contact between company and KOLs, and this contact is not only 
limited to scientific exchange but also to potential working collaborations with the company. This 
role is extended to many other physicians, with whom MSL interacts. And this particular aspect 
highlights the MSL role as an essential driver of medical education and a catalyst for product 
growth in the market. 
The MSL may have a KOL proactive or reactive outreach strategy or approach. Interestingly, 
many companies have made a clear distinction between activities that can be considered 
proactive from the ones that are considered reactive, such as responding to unsolicited requests 
for information. While there is a consensus in separating these different concepts, the 
assumptions behind these two different approaches have a wide variation between companies. 
Common to all visions is the fact that the MSL always acts in compliance with high ethical and 
deontological standards, and it is indispensable to avoid misunderstanding between the MSL role 
and the one of sales representatives.19 
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“Nowadays, MSLs are the human face of science for the pharmaceutical industry. They should 
be able to earn KOL’s respect by managing human-to-human relationships with a scientific content 
on their speech. As such, MSLs are required to master skills in the areas of communication, science 
and human behavior in order to perform their job proficiently, thus giving a significant boost to 
their company’s performance while bearing in mind that this business channel should maintain an 
arm’s length distance from sales and marketing to prevent misperception between these different 
roles.” Dr. Pedro Faber Branquinho, Senior MSL AstraZeneca 
4.2.4. Role as internal thought leader 
As stated before, Medical Affairs teams are assuming a more prominent role during early 
phases of drug development.2 Within Medical Affair’s teams, the MSLs provide important 
contributions across the product development spectrum; initially, prospecting and profiling KOLs 
and thought leaders for their companies, and exploring the therapeutic arena; subsequently, 
disseminating scientific data, facilitating clinical research and monitoring competitive landscape in 
their therapeutic specialty (Figure 2 – Contribution of MSLs across product lifecycle). 25 
Figure 2 – Contribution of MSLs across product lifecycle (adapted from Chin, 2007).  
The insights gathered by the MSLs in KOLs and thought leaders’ interactions, along with their 
therapeutic expertise and competitive intelligence, enable companies to implement conscious 
and informed strategic decisions across multiple sectors, including R&D, Medical Affairs and 
Marketing. 25 
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Furthermore, the MSLs have also the responsibility of identify internal training needs 
concerning product, disease and therapeutic area. As company’s internal scientific and medical 
knowledge experts, the MSLs give their inputs to educational contents and provide specific 
training to sales force or other company’s staff, as necessary. 25 
But the internal role of the MSL is not only limited to training and insight-driven performance. 
Many companies have implemented structured MSL mentoring programs in which a mentor 
(usually a senior MSL) is assigned to a protégé (new employee) with the purpose of introducing 
him/her to role expectations, providing a perspective of company’s culture and values, facilitating 
team integration, and mentoring him/her towards the leadership mission. 26 
4.2.5. Compliance to high ethical standards 
The pharmaceutical industry continues to undergo significant change with respect to how 
companies interact with medical community and HCPs. The increased pressures from regulatory 
authorities and demand for more transparency have made companies and physicians susceptible 
to investigation for fraud and misconduct.29 
This new regulatory arena increased physicians’ reluctance in collaborating with industry, 
fearing that it may jeopardize their credibility. It turns to be absolutely essential that 
pharmaceutical companies’ approach to medical community has to be ethical, compliant and 
even stricter than the current regulatory dispositions and deontological guidances. 
In Portugal, the MSL activities are regulated by Decree-Law nr. 176/2006 – Estatuto do 
Medicamento14, Decree-law nr. 330/90 – Código da Publicidade15, Deliberation nr. 044/CD/220816, 
with which Deontological Code from APIFARMA17 is aligned. It is important to state that these 
regulations are not exclusive for Medical Affairs activities or MSL functions but represent 
promotional pharmaceutical activities as a whole, not making a clear differentiation between 
promotional or non-promotional activities, with the exception of Medical Information and Patient 
Safety activities which are clearly a legal requirement. 
 Therefore, companies opt to create their own interactions codes and ethical guides based on 
the interpretation of the regulatory standards and deontological codes. Moreover, it has been 
established that MSL interactions with KOLs must have a non-promotional nature and scientific 
exchange is required to be on-label, unless the physician has formally requested it otherwise. 
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The MSL should always comply with the established normatives, ensuring that its behavior 
adheres to the highest ethical standards, contributing to company’s public recognition and 
reputation as trustful partner. 
4.2.6. MSL performance metrics 
Pharmaceutical companies are reformulating their hiring practices and organizational structure 
mostly due to regulatory compliance concerns. The focus shift from Sales and Marketing to 
Medical Affairs made companies face the challenge of developing and implementing metrics to 
assess MSL performance. However, measuring MSL activities is not an easy task due to the fact 
that relationship building, collaborative activities, value of ideas and insights are not quantifiable 
variables. 25 The current responsibilities and objectives of an MSL do not fit into the traditional 
field-based sales model. 
«I believe that we are still seeking for an ideal way to compare and evaluate the work of an 
MSL; and the current metrics, based on quantity of visits to a predefined KOLs panel do not reflect 
the richness of the work done, and do not show as well, by exclusion of qualitative metrics, the 
active involvement in the medical strategic product planning or the impact of the MSL role in 
generating and dissemination relevant scientific evidence.» Dr Filipe Branco, Senior MSL 
AstraZeneca. 
The MSLs consider frequency metrics as following a sales-centric approach and therefore 
unadjusted for compliance reasons, however qualitative metrics are perceived as insufficient from 
business executives' point of view. The fact is that quality matters for the purpose of appraisal of 
MSL performance. In contrast, quantitative metrics may be easily fudged and ultimately provide 
minimal insight into true performance. In an attempt to overcome metrics controversy, 
companies use a blend of qualitative and quantitative metrics to support and communicate MSLs 
value to corporate stakeholders.25, 30 
Despite MSLs metrics include qualitative objectives there is a rising tendency to assess MSLs 
performance based on quantitative measurements, conferring the misperception that the nature 
of the MSL is analogous to the one of Sales Force Representative.  
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4.3. Practice trends across the pharmaceutical industry 
Over the last years, the increasingly constraints of resources on healthcare systems and a 
product competitive landscape have pushed pharmaceutical companies towards a tangible 
demonstration of the medical and economic value of their products to medical community, 
institutions and society.1 
In order to demonstrate value, Medical Affairs departments have availed themselves of field-
based professionals with solid scientific backgrounds, MSLs, to collect insights from a broad range 
of medical influencers and decision-makers feeding back to companies’ strategic plans, tailoring 
and continuously updating the definition of value. This movement allowed companies to better 
shape the communication of its products and also to create a stronger scientific bond with 
medical community.1 
Although the function does not exist in every company or even country, in Europe there has 
been an increasing number of MSLs across industry. Up until 2010, multinational pharmaceutical 
companies have privileged the implementation of MSL teams on the USA market, with small 
expression in the European and Asian markets. Data from 2012 show that, globally, there were an 
exponential number of companies reporting the integration of MSL in their medical staff: 74% in 
Europe (compared to 64% from a study conducted in 2010) and 42% in Asia (21% in 2010).5 
As the number of deployed MSLs tends to grow, so does their specialization. This trend 
towards specialization is more prominent in the USA market and thereby the MSL may assume 
different responsibilities:30 
 Provide therapeutic area and/or health outcomes research support to Payer customers 
exclusively; 
 Interact with external clinical investigators and potential investigators in the support of 
trials platforms, as Clinical Trials Liaison; 
 Ensure broad coverage of HCPs below the KOL level targeting registered nurses, nurses 
practitioners and physicians assistants, as Clinical Education Liaison; 
 Work in alignment with field sales, being responsible for supporting the brand while 
building relationships with thought leaders, as Thought Leader Liaison; 
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 Work in alignment with field sales, being responsible for developing speakers; 
 Produce product training materials, disease-state materials and synopses from medical 
conferences, as Field-based Disease Education Resource Manager. 
As MSL roles and responsibilities have evolved to fulfill a wider extent of demands, the profiles 
and educational backgrounds of MSLs are of critical relevance. In a survey applied to Medical 
Managers and Medical Directors conducted across the industry, when asked about the 
educational profile for MSLs, 66% referred that an advanced degree (MD or PhD) was essential to 
be integrated in theirs company’s teams, 27% considered that an health-related undergraduate 
degree was sufficient, and 7% reported that non-health related undergraduate degree was the 
minimal requirement to accomplish MSL functions.31  
Based on the historical evolution, the MSL role and responsibilities presumably will continue to 
develop, adapting to market demands, an increasingly more restrictive environment and a drift to 
specialty care focused business, as opposed to primary care business. 
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5. A journey into the pharmaceutical industry: my experience as MSL 
5.1. AstraZeneca: host company profile 
AstraZeneca is a multinational biopharmaceutical company, and one of only a handful to span 
the entire chain of a medicine from discovery, early and late-stage development to 
manufacturing, distribution, global commercialization of primary care and specialty care 
medicines, whose main focus areas include some of the most serious contemporary illnesses: 
Cardiovascular and Metabolic, Oncology, Respiratory, Inflammation and Autoimmunity, and also 
Infection, Neuroscience and Gastrointestinal diseases. 
It employs over 50,000 people, in more than 100 countries, and its medicines are used by 
millions of patients worldwide. 
Based in London, AstraZeneca was formed in 1999 when Astra AB of Sweden merged with 
Zeneca Group PLC of the UK. According to IMS32, AstraZeneca is one of the top-five leading 
biopharmaceutical corporations in Portugal, ranking eighth in terms of sales worldwide. 
AstraZeneca Portugal is located in Queluz, in the outskirts of Lisbon, and employs 160 workers 
within several departments: Corporate Affairs and Market Access, Finance, Human Resources, 
Sales, Marketing, Medical and Regulatory Affairs.  
The Medical and Regulatory Affairs Department integrates 21 professionals and it is structured 
according to specific functional units: regulatory affairs, medical information and patient safety, 
clinical research, quality assurance and five Medical Affairs therapeutic areas (respiratory, 
oncology, central nervous system, cardiovascular and metabolic).  
Each company may structure its medical department differently, depending on the dimension 
and culture of the organization. The AstraZeneca Portuguese Medical and Regulatory Affairs 
Department (MD) is headed by a Medical Director, Dr Ana Rita Lima, who is supported by a 
multidisciplinary group of life-science and health-science background professionals and 
administrative staff (Appendix A – AstraZeneca’s Medical and Regulatory Affairs Department 
Organogram). Within the Medical and Regulatory Affairs Department, these professionals take 
the roles of:  
 Regulatory Affairs, Medical Information & Patient Safety Manager; 
 Nominated Signatory; 
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 Patient Safety & Medical Information Specialist; 
 Regulatory Affairs Manager; 
 Regulatory Affairs Advisor; 
 Clinical Research Manager; 
 Quality Assurance Manager & Qualified Person; 
 Quality Assurance Specialist; 
 Medical Affairs Manager (MAM); 
 Medical Science Liaison (MSL);  
 Medical Assistant. 
As Medical and Regulatory Affairs Department trainee, and specifically as an MSL, I was under 
the scientific guidance of the Medical Director, Dr Ana Rita Lima, and under supervision of the 
senior MSL Filipe Branco and the MAM Rafael Fernandes. 
5.2. Internship 
As an integrant part of the master degree in Pharmaceutical Medicine, the purpose of this 
internship was to blend real on-the-job experience with an extensive overview of the 
pharmaceutical industry environment and the competences gained during the curricular part of 
the master. This internship was held in the Medical and Regulatory Affairs Department of 
AstraZeneca Portugal, during the second year of the master’s degree. It started on 8th of April 
2014 and it is planned to last approximately nine months, until the 30th of November 2014. 
5.2.1. Goals and description 
The main goal of this internship was to develop key competences which will enable me to 
perform the role of a MSL in a multinational biopharmaceutical company, in Cardiovascular 
therapeutic area, acting as a medical customer-facing resource who supports a market-leading 
brand in Portugal; the focus of my role was particularly targeted to the development and 
implementation of Continuous Medical Education programs and associated management of KOLs 
and regional or OPs. 
During the first weeks of the internship an induction program (Appendix B), common to all 
trainees and newly assigned employees, was rolled out. It comprised an introduction to 
AstraZeneca Portugal, held by representatives of different departments. Through this program it 
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was possible to get in touch with the company’s structure, mission, culture and values. 
Afterwards, with a progressive grade of complexity, a handful of specific and comprehensive 
training (in-person programs, online training and self-study) required to the MSL performance and 
related therapeutic area of expertise were delivered.  
AstraZeneca’s knowledgeable mentors, senior MSL Filipe Branco and MAM Rafael Fernandes, 
have provided me with mentoring and on the job coaching while professional hands-on 
experience was being gained.  
The internship was developed in the Cardiovascular area, in the dyslipidemia disease area, in 
support to rosuvastatin – a reference molecule commercialized by AstraZeneca as Crestor©, which 
although is seen as a mature end-of-lifecycle product, it represents 42.2% of the turnaround sales 
in Portugal. (Figure 3 - Rosuvastatin’s lifecycle) 
 
  
                                                      
  
 
Figure 3 – Rosuvastatin’s lifecycle 
 
5.2.2. Core activities within Medical Plan 
The management of a pharmaceutical product during its lifecycle requires an immense amount 
of operational planning and effective execution. 
The strategic preparation of the market by Medical Affairs starts at least two years before a 
product’s launch and continues throughout its lifecycle. From laying the groundwork of product 
understanding by the market, to prompting adjustments until patent expiry, Medical Affairs 
informs competitive product messaging, based on clear medical and scientific insight.  
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To facilitate planning, the Medical Affairs needs to be coordinated as a set of internal and 
external activities, defined by time frames and financial investment decisions, that are prioritized 
according to the product cycle phase and respective goals – the Medical Plan (MP).  
The MP has a flexible and dynamic nature that is adapted to the characteristics of the product 
itself and its importance to the company portfolio and stakeholders. Although being a die out 
product, Crestor© is a blockbuster and it still represents a critical piece of AstraZeneca’s business. 
In fact, it is still seen by the medical community as a standard treatment for hypercholesterolemia 
and the prevention of major primary cardiovascular events. The responsibility of having such a 
product implies that AstraZeneca continues to invest time and resources into it, especially in 
medical activities, in order to assure that patients who need continue to receive the best 
treatment available.  
Each element of the Medical Affairs team is responsible and accountable for a different set of 
activities of the MP: Regulatory Affairs, Quality Assurance, Medical Information and Patient Safety 
specialists, Medical Managers and MSLs work to support the product medical activities and 
customers, serving the main purpose of educating internal and external stakeholders through the 
delivery of accurate, comprehensive and unbiased information on the product, while being 
compliant to the highest ethics standards and regulatory obligations.  
The internal and external activities driven by the MSL in support to Crestor© MP are described 
below. 
5.2.2.1. Internal 
Crestor© internal medical activities were focused on developing sales force scientific 
capabilities, i.e. by training them on the medical unmet need, disease area, product and 
treatment algorithms and guidelines.  Furthermore, as an MSL I had a clear role in providing 
medical and scientific expertise to support marketing activities (promotional material reviews, 
internal scientific updates, identification of potential speakers for promotional events), and also in 
response to medical information inquiries, as a scientific advisor of Medical Information. 
My experience as MSL trainee allowed me to plan, prepare and deliver scientific training 
sessions to sales force and marketing representatives related to new clinical practice guidelines, 
the basis of anatomy, physiology and pathology, product characteristics, new indications and 
clinical studies updates. This was a dynamic process that allowed me to collaborate directly with 
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training department representatives, getting valuable feedback to my performance as a scientific 
trainer. 
I was also involved in the support to marketing activities such as educational workshops 
involving healthcare professionals, and the review of marketing material, which provide me with a 
continuous interaction with the marketing department. The workshops has as a key target 
pharmacists, and had the main objective of raising awareness around cardiovascular risk and the 
importance of controlling major risk factors such as hyperlipidemia. My role in those workshops 
was to liaise with the speakers, usually Cardiologists, assuring an alignment of their 
communication and key messages.  
Another activity that I had contacted with was the review of promotional materials. I was not 
able to do it autonomously but I could follow the process under the guidance of my mentors. This 
was is a very thorough process; all data were carefully scrutinized to guarantee that all 
information was on-label, scientifically accurate and balanced, according to all legal and 
regulatory requirements on promotional practices as well as company’s policies and standards. 
Occasionally, I was also requested to backing up medical information services with specific 
data required by HCPs. Most of these requests were related to new clinical studies or information 
about unapproved uses of rosuvastatin. 
5.2.2.2. External 
Crestor© external medical activities were focused on KOLs and OPs scientific exchange 
objectives (which included discussions about clinical practice guidelines, as well as potential new 
indications or areas of study whenever requested by HCPs), competitive intelligence (monitor 
literature and trial results, collect and report relevant insights gathered from KOLs about unmet 
needs, disease management, including treatment trends and competitors space) and medical 
education projects. 
As MSL trainee, my activities were focused on the management of Continuous Medical 
Education projects, previously defined in the educational programs included in the MP, entailed 
to engage KOLs and OPs on scientific discussions around the unmet needs on CV risk management 
and dyslipidemia treatment, while building KOL advocacy, and to drive peer-to-peer 
communication and education, in a non-promotional context. 
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Strategically, and in line with the Marketing strategy and product positioning, the medical 
education programs were developed to reinforce Crestor’s© positioning as a gold standard 
treatment in high cardiovascular risk patients, for patients who most benefit from it. This 
positioning was communicated to physicians of non-cardiovascular hospital specialties who 
frequently follow those patients but not seldom recognize that increased CV risk (e.g. 
Infectologists, Rheumatologists, Neurologists, Urologists and Gynecologists, Internists, as well as 
General Practitioners - GPs).  
The management of Crestor’s© medical education projects requires a strict coordination 
between several internal and external stakeholders where the MSL acts as the linking piece 
between all of them. On one hand, the MSL is responsible for engaging speakers – usually a 
regional or national OP –, aligning the scientific contents with the objective of the program, which 
has to follow the brand’s strategy and positioning, and tailoring it to the audience needs and 
specificities; on the other hand, he/she coordinates the activity with the local First Line Manager 
and Sales Force teams making sure there is an adherence of the participants to the program; 
finally, an important planning activity seats with managing properly the third party or agency that 
is contracted to support the logistics and communication, which is particularly useful in bigger 
dimension meetings normally involving larger audiences outside of hospital setting (e.g. GPs 
regional meetings); collects insights and reports post-project feedback.  
During my training, I had the chance to receive on the job coaching with the senior MSL Filipe 
Branco, by closely following the multidimensional management of these medical education 
projects. More recently I was given the opportunity to manage them autonomously.  
The projects are described below. 
 
Continuous Medical Education projects 
«Porquê Arriscar?» 
This was a Continuous Medical Education project whose main objective was to raise the 
awareness and educate GPs on cardiovascular risk assessment and management, delivered as 
smaller dimension local meetings. Key responsibilities of the MSL in this specific project included 
the engagement of regional or national KOLs, managing their contribution to the definition of the 
program agenda, and preparing them as speakers by means of a strong scientific briefing, as well 
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as aligning on a plan with the Sales Managers and Sales Force to mobilize resources and 
participants for the program. 
«Pontes de Risco» 
This project aimed at reaching out to physicians of hospital non-cardiovascular specialties 
(Infectious Diseases, Rheumatology) who manage patients with high cardiovascular risk. The 
management of this project involved the invitation of national KOLs and hospital physicians of 
non-cardiovascular specialty. After the invitation of the KOL, it was necessary to establish his/her 
contribution to define an agenda for the medical program, his/her preparation as a speaker, as 
well as the alignment with the Sales Managers and Sales Force team to mobilize resources and 
logistics to support the program participants. 
«Sessões VIVA» 
These sessions presented the results of an epidemiological population-based study conducted 
by the Portuguese Society of Cardiology to estimate the cardiovascular risk in the general 
Portuguese population. Along with the epidemiological data presentation and discussion, in each 
session there was an allocated time to raise awareness on cardiovascular risk which was done by 
discussing case-studies and training participants on cardiovascular risk calculation.  The study 
investigators, representatives of the Portuguese Society of Cardiology, led these sessions. The 
«Sessões VIVA» where tailored and delivered to Internal Medicine physicians, and had an active 
involvement of the Heads of Department. The MSL role in this project included the invitation of 
the researchers who presented the study, the invitation and involvement of the Head of 
Department for the session, the discussion and establishment of the objectives for the session 
with both, as well as the alignment with the Sales Managers and Sales Force team for the 
mobilization of logistical resources and participants for the program. 
«Sessões PGRx» 
The sessions were led by a national KOL already pre-identified, and had the objective of 
training GPs in CV risk assessment and management, having as a basis and context the spreading 
of a recently published French real-world evidence (RWE) study in the statins area – the PGRx –, 
with discussion of real clinical cases. The MSL role was to brief the speaker on the session’s 
objective and to liaise with the Sales Force assuring a good level of HCPs participation. 
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5.2.3. Other activities 
During my internship I have experienced other enriching activities, although some not directly 
related to the MSL role, which must be mentioned due to the importance that they have had in 
my professional and personal development. 
On a regular basis, AstraZeneca Portugal promotes internal scientific sessions open to all 
company’s departments, integrated in a project named Health Me. These sessions take place 
during one week, several times a year, each of them focusing on a specific medical theme, 
introducing AstraZeneca’s related portfolio and pipeline.  All of these educational weeks involve 
the participation of KOLs or experts on a given field and Medical Affairs staff, who are also 
responsible for the planning and delivery of the events.  
In this context, I had the opportunity to actively participate in the Respiratory Care sessions – 
“Inspiration Week” – where the basic disease concepts of Asthma and Chronic Obstructive 
Pulmonary Disease (COPD), national and worldwide epidemiological data, as well as the 
importance of screenings and healthy behaviors were presented. AstraZeneca’s current and 
future pharmaceutical arming in these disease areas was also presented. Other highly interesting 
sessions were also delivered under the Oncology Care week – “Courage Week”; these sessions 
allowed employees from different departments to refresh and learn concepts about different 
types of cancer, the physiopathology underneath this disease, the numbers behind the facts, the 
screening and treatment options, AstraZeneca’s R&D contribution through clinical studies for the 
evolution of cancer care, and AstraZeneca’s portfolio and pipeline in this specific area. Until the 
end of the year, at least two more thematic weeks will be delivered – the “Love Week” and the 
“Sweetness Week” – covering Cardiovascular and Metabolic disease areas, respectively. I have 
already committed to actively contribute as a team member in the management of one of these 
thematic weeks. 
As part of the launch of two new Diabetes products, a one-day training, led by a senior MSL – 
Ana Penha – and an Endocrinologist – Dr Laura Guerra –, was delivered. This training covered the 
diabetes basic mechanisms, epidemiology, treatment options, new drug’s mechanism of action, 
and differentiation versus insulin treatment. This training was directed to all internal stakeholders 
involved in the Metabolic area and, despite being allocated to other therapeutic area, I also had 
the opportunity to attend this training session. This allowed me to get a deeper knowledge about 
this fascinating disease, which it-self contributes significantly to the high CV risk of many of our 
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patients, and to have a glimpse on the best therapeutic options available to manage this 
multidimensional disease. 
Another project in which I was personally involved came out unexpectedly and it was 
concerned to Safety, Health and Environment.  Being my-self an HCP with many years of clinical 
practice in the public sector, my ultimate goal is to contribute meaningfully for people’s wellbeing 
and health improvement. For that reason I gladly accepted the invitation to collaborate in the 
production of an ergonomic guide to AstraZeneca’s employees, giving my insights and 
contributing with my technical expertise. 
Over this period I was also given the opportunity to receive training in the hospital setting l and 
have had contact, as an observer, with cardiac catheterisms – a minimal invasive surgical 
procedure with both diagnosis and intervention purposes at the coronary arteries level, in 
Hospital de Santa Cruz, under the guidance of Dr Manuel Almeida, Cardiology KOL. Behind the 
obvious contributions to deepen my knowledge in the CV area, this experience allowed me to 
interact directly with many other Cardiologists, collecting insights about their clinical practice, its 
limitations and unmet needs. 
To complement my internship, I have also done side-by-side coaching with Sales 
Representatives and senior MSLs. The coaching with sales representatives was very valuable.  It 
allowed me to experience their field interactions with physicians, the objections that are raised 
during the visit, learn how to effectively use triggers to get the message across, and collecting 
insights related to the medical needs of those physicians. The visits also allowed me to introduce 
myself and thus have my first contact with some KOLs and OPs. To sum up, this experience has 
allowed me to have a better understanding, from a purely commercial perspective, of the 
dynamic between AstraZeneca’s Sales Force representatives and the medical community at the 
hospital level. 
Another activity in which I was enrolled in, and that was not initially included in the induction 
plan, was the MSL certification process. This process was implemented globally across 
AstraZeneca as a way of standardizing MSL capability building and development across markets, 
and represented a valuable way to validate key competences and skills of the MSL, which are 
essential to his/her performance. Globally, my communication skills and my ability to present 
scientific contents to medical audiences were evaluated. My performance was rigorously 
scrutinized by the Cardiovascular & Metabolic MAM, Rafael Fernandes, the MSL mentor, Filipe 
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Branco, and the Training Department Coordinator, Paula Serralha, who kindly reported back the 
results in a very positive and constructive way.   This was a very important milestone in my 
professional development, since I have obtained rich and valuable inputs in what regards the 
planning, preparation and presentation of scientific sessions, which really had an impact in my 
daily work.  
Finally, the engagement in one-to-one training sessions with top KOLs was another important 
part of my experience as trainee. These sessions were directly related to the cardiovascular area 
of expertise and have contributed significantly to increase my scientific and medical knowledge, 
and grow the enthusiasm for being part of AstraZeneca. 
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Results and Critical Appraisal 
Being responsible for rosuvastatin’s (brand name Crestor©) medical scientific liaison plan 
allowed me to develop the following activities: 
 I have written and updated eight training documents/manuals specifically designed for 
supporting the scientific preparation of different internal stakeholders, such as Sales 
Representatives and other staff from marketing and sales departments, concerning the 
following topics: 
 Rosuvastatin clinical studies – Galaxy 
 Cardiovascular Anatomy, Physiology and Pathology  
 Cardiovascular risk in elderly people 
 Cardiovascular risk in autoimmune diseases – Lupus, Rheumatoid Arthritis, 
Psoriasis 
 Update on 2013 American Guidelines on Blood Cholesterol  
 Update on 2012 European Guidelines on Dyslipidemia Management 
 Rosuvastatin Summary of Product Characteristics (SPC) 
 Update on rosuvastatin clinical studies – new indication 
 I have conducted scientific training sessions directed to Sales Representatives and other 
staff from Marketing and Sales Departments related to the themes I had previously 
prepared (mentioned above).  
 I have been involved in marketing material reviewing, specifically in the review of an 
interactive detailing (iD) for Sales Force use, concerning Acute Coronary Syndromes. 
 I have been present in several AstraZeneca’s external Marketing and Medical events: 
 Pharmacies workshops  
 Heart Beat interactive platform events 
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 «Porquê Arriscar? » 
 «Sessões VIVA» 
 Hospital clinical sessions 
 I have liaised with KOLs and OPs in the context of marketing activities and medical 
activities (medical educational projects), setting the scientific agendas, discussing meeting 
objectives, and aligning on key messages: 
 Pharmacies workshops 
 «Porquê Arriscar?» 
 «Sessões VIVA» 
  I have also cooperated with AstraZeneca’s Medical Information and Patient Safety services 
in specific unsolicited medical requests related to rosuvastatin, namely off-label uses and clinical 
studies requests. 
 Regarding the internship limitations, it was not always clear how much support or how much 
autonomy I should have had. Sometimes it was difficult to understand the expectations and 
where to start for some of the medical activities I had to assure as a trainee. To overcome this 
difficulty, I have begun to define very clearly the requirements and deadlines for all medical 
projects under my responsibility, and developed structured spreadsheets with action points and 
status for the activities planned. This was a great way to define timelines and plans of actions, but 
also to keep projects information organized and updated. 
These activities, which were delivered in close cooperation with internal and external 
stakeholders, have given me the chance to sharpen my communication and presentation skills, to 
raise my self-confidence when interacting with KOLs and OPs, to acquire a comprehensive 
knowledge on dyslipidemia and CV risk management, as well as on CV therapeutic area as a 
whole, strengthening my scientific preparedness in a disease area that is close to my heart.  
Moreover, the experience of working in an inter-departmental cross-functional environment was 
really challenging and, simultaneously, rewarding, having allowed me to develop my ability to 
define priorities and to build on my natural strengths – collaborative, problem-solving focused, 
team player, customer oriented, results driven, and strong communication skills. 
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6. Closing remarks 
Clearly, due to increasing regulatory pressures, healthcare systems restructuring, more 
transparency in all pharma companies activities directly related to patient data and HCPs 
engagement, as well as socio-economical changes observed both in Europe and North America, 
we are observing a strategic shift in pharmaceutical industry, where the focus is no longer 
directed to commercial teams only, but it is progressively being allocated to Medical Affairs 
teams. 
Medical Affairs teams have become a privileged source, and actually a privileged channel, of 
interaction with medical community. The MSLs are considered to be the propellers of these 
collaborative relationships and scientific knowledge exchange, acting as reliable and trusted 
partners of KOLs, collecting and reporting their insights back to pharmaceutical companies, which 
ultimately are translated into more tailored strategic plans. Thinking of the value they deliver to 
the medical community, the MSLs help physicians to stay up to date, by delivering higher quality, 
relevant and balanced medical information, as well as cutting-edge science to address unmet 
clinical needs and provide better patient care.  
The presence of MSLs in companies’ Medical Affairs teams has been continually increasing 
over the last years, however it cannot be truly considered a new emerging role, since it does exist 
since the late 60’s. But, now more than ever, with the featured role of Medical Affairs, MSLs are 
becoming an unquestionable essential resource. And it is interesting to note that there is also an 
increasing trend towards MSLs specialization, mostly related to clinical trials support, education 
resource management objectives, and health outcomes research needs, especially since we are 
seeing the increasing need to communication value to new customers, as is the case of payers. 
Despite core MSLs functions resemble between companies, there are aspects that differ 
concerning metrics and management responsibilities, and each company shapes the function 
according to its Global strategic vision, lifecycle phase of its portfolio and pipeline, and local 
market specificities. Unfortunately, in Portugal there is no benchmarking data on MSL groups 
across pharmaceutical industry. Therefore, it was not possible to analyze the past or current state 
of the function, nor the inherent particularities of this role in Portuguese market. 
Regarding physicians’ Continuous Medical Education, pharmaceutical industry plays an 
important role, and more so in Portugal. The value of this core pillar of the Medical Affairs activity 
is not only due to the scientifically solid nature of the physician-MSL interaction, but also due to 
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the investment of time and resources behind the implementation of relevant Continuous Medical 
Education programs, with HCPs consensually recognizing the benefits of such programs to their 
continuous training and development, with an impact on patient care management. Although 
outside of the scope of this report, it is worth mentioning that there is a lot more to explore 
concerning Continuous Medical Education, especially because of the marked contrast between 
countries’ accreditation systems, professional impositions and the challenging role of 
pharmaceutical industry in those contexts, not to mention the different funding systems in 
different countries. 
As a result of a deeper involvement in all drug lifecycle, with more cross-functional 
responsibilities and an intensive KOL interfacing, the MSL is gradually assuming a critical role in 
pharma companies business success, not only in pre-launch and launch phases, but also in 
managing the life cycle of more mature brands when these are still relevant to the business as is 
the case of Crestor®. The MSL is therefore an internal thought leader, clinical catalyst and external 
voice, and these different roles’ relative weight is more or less prominent depending on the 
lifecycle of a given product. 
However, some challenges still remain, and this was also observed during my trainee 
experience. The demarcation of MSL role from a sales representative role, which can work against 
cross-functionality and create silos, the demonstration of the real MSL value to companies’ 
business leaders, the development of appropriate metrics that really reflects the nature of the 
role, and finally the need of an appealing career development path. 
During my almost nine-month long experience as Medical Scientific Liaison trainee, I had the 
chance to progressively undertake more responsibilities, initially developing my scientific 
knowledge and building on my educational and professional background, and subsequently 
preparing and delivering scientific training and managing medical education projects more 
autonomously. 
During this transition time, I took a wide variety of tasks that covered almost all of the 
activities performed by an MSL. Although the emphasis of this internship has pivoted around the 
role of the MSL in Medical Education projects, it was possible for me to experience other related 
activities, namely internal ones. Within the MSL role, I would have valued to have had more 
contact with clinical research activities, but this was understandably not possible due to the end-
of-cycle stage of Crestor®.  
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At AstraZeneca the MSL time allocation takes into account the customer facing nature of the 
role and therefore 70-80% of the time is spent in interaction with physicians. During the 
internship period my interactions with KOLs and OPs were all related to projects’ management. 
Peer-to-peer scientific discussions require a high level of expertise that is only achieved with 
intensive training and years of practice. As someone said to me: «Every expert was once a 
beginner. You are just getting started». Nevertheless, I had the chance to accompany a senior 
MSL in the field, to better understand the dynamic and the primness of these scientific 
interactions.  
This internship was an excellent way of putting in practice and developing in a real-life setting 
concepts acquired during the master, and a chance to contribute with my knowledge, background 
experience, resilience and dedication to AstraZeneca’s values and purposes. In every task I was 
assigned to, aiming at small or great achievements, I have always strived to reach excellence. It 
was also a great opportunity to develop a personal and professional networking and to 
collaborate with a fantastic team of very talented people.  
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Appendix B - AstraZeneca’s Induction Programme 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sessão realizada                                                                    Sessão não -realizada 
Activity Objectives Delivery Method Documents / Links
Timing / Date
Meeting Room
Self Check & Comments 
/ Notes
Politica Safeguarding Company Assets & 
Resources 1st week Sessão não realizada
1st week Sessão não realizada
Processo de Admissão
Contrato de Estágio
Sessão Realizada
AZengage - Ferramenta de 
RH
Validação de Dados pessoais e preenchimento 
dos restantes
Página AZengage
Sessão Realizada
Telemóvel
Procedimentos
Realizar procedimentos relativos ao Telemóvel
Meeting with 
Raquel Sousa
2nd week
Sessão Realizada
Consulta de informação
Mission & Vision
Consulta de informação
Our science
AZ Institutional
Comunicação Interna
Obter uma Visão Global sobre a AZ Portugal 
Iniciativas Internas
Meeting with
Célia Machado
Sessão Realizada
Documentos para consultar
 Semana 21 Abril
Filipe Branco
Meeting  - Orientador do Estágio
Your:AZ_Global Scorecard 2014
 Semana 21 Abril
Filipe Branco
Overview do Departamento
Departamento - Objectivos e Prioridades 
Estratégicas
Contextualização do Estágio
Meeting  
Orientador do Estágio
Diretor do Departamento
Semana 21 de Abril
Politica SHE Sessão Realizada
Politica Edifício Sem Fumo Sessão Realizada
Actuação em situações de emergência Safety Sessão Realizada
Localização e responsáveis pelas caixas 
de 1º socorros Sessão Realizada
Equipa de Apoio Médico Sessão Realizada
Registo de Acidentes e Incidentes Form. de registo acidentes Sessão Realizada
Folheto Sessão Realizada
Regras separação Sessão Realizada
Business Continuity Plan
Risk Management
Business Continuity Plan
Meeting with
Alexandra Nunes
IRM / BCP Local page
Sessão Realizada
AZ Global Intranet
Global Policies
Documentação - 
Leitura realizada 
AZ Local Intranet
Corporante Governance
Documentação - 
Leitura realizada 
Politicas AZ Realizar formação em Data Privacy E-Learning - Data Privacy Data Privacy - Protecting Personal 
Information incluido no treino de MSL
E-learnings - 
 Concluído
Código de Conduta
Procedimento sobre report 
de Incidentes
Conhecer a Politica: Código de Conduta E-Learning - Código de Conduta E-learning - AZ Code of Conduct
E-learnings - 
 Concluído
Compliance
Formação em CDTI
Overview área de Compliance na AZ
Conhecer a politica de Interacções externas e seu 
impacto 
Meeting with
Paula Serralha
CDTI Intranet page
11-Abr-14 Sessão Realizada
Continuous Assurance
Conhecer processo de Continuous Assurance
Compreender o papel de colaborador AZ
Continuous assurance Intranet page
Sessão Realizada
Quality Assurance
Product Security
Qualidade dos produtos
Procedimento de gestão de queixas Sessão Realizada
Nominated Signatory 
overview
Nominated Signatory - Papel, responsabilidades e 
desafios
AZ Local Intranet
Meeting with Inês N Guedes
Nominated Signatory Page_Intranet 
local
Sessão não realizada
Contratos na AZ Processo de Contratos na AZ
Meeting with
Sara Macedo
Intranet_Contratos
Sessão Realizada
Submissão de Despesas Mensais
Meeting with Susana Santos (on 
the job)
T&E Intranet
2nd week
Conhecer o processo do Doa´s (Delegation  of 
authorities)
Leitura da informação e 
documentação DoA_Intranet
Farmacovigilância
Info Med
Procedimentos
Meeting with Isabel Cruz / Ana 
Paula Rita confirmar quais os treinos on line 
que deve fazer Sessão Realizada
Formação  Patologia e 
Produto
Formação em Crestor
Meeting
Treino - Lourenço Pereira
MSL - Filipe Branco Sessão Realizada
Overview Área de Vendas
Estrutura de Vendas Primary Care e Objectivos 
2014
Meeting
Aníbal Carvalho Sessão não realizada
Overview Marketing 
Estrutura Marketing e Objectivos 2014 
Objectivos Crestor
Meeting
Sofia Correia
Igor Costa Sessão não realizada
Clinical Trials Desenvolvimento Clinico do Medicamento
Meeting 
Sandra Barbosa
Sessão Realizada
Formação em Atlas
Submissão de projectos 
Consulta de material disponível da AZ Global
E - Learning e 
Treino presencial - Line 
Manager
LM  solicita ao Global Commercial Services: 
GlobalCommercialServices@astrazeneca.com - a criação do 
utilizador, enviando o PRID e Endereço de Email.
Esta formação não será realizada 
numa 1ª fase.
Avaliar posteriormente se  
justifica o terino Sessão não realizada
Formação em Veeva Ferramenta para a actividade dos MSL´s Presencial
11 Abril, 8 de Maio e mais uma 
data Sessão Realizada
Formação em Condução 
Defensiva
Classroom and Driving  training
A considerar se utilização de 
carro AZ
Sessão não realizada
AZ Local Intranet 
Meeting with Cláudia Sousa
Overview da AZ - Global e 
Local
Induction Plan Liliana Cruz
Inicio - 08 Abril 2014
Politica SHE
IS / IT Material & Tools
IT Tools
Acesso Remoto
Wireless - opções disponíveis
Acessos às Drives Public, Departments, etc
IS / IT code of conduct
Meeting with Miguel Rodrigues
Meeting with
João Dias 2nd Week
AZ performance - Objectivos e Prioridades 
Estratégicas
Formação de 
procedimentos na 
Área Financeira
Apresentação da Politica SHE e SHE Committee 
local
Consulta da documentação 
e
Meeting Area SHE
Primeiros socorros
Recolha selectiva de resíduos
Politicas AZ Conhecer as Politicas Globais e Locais 
Missão e Visão
Conhecer a Missão e a Visão da  AZ
Posicionamento Cientifico
Computer_usage_p
olicy__PT
Portugal Scorecard 
2014
